China To Issue Plan For Invigorating Bioindustry
This article was originally published in PharmAsia News
China's National Development and Reform Commission is pushing for the development of the bioindustry, which so far has been little impacted by the global financial crunch. The sector grew 25.5 percent in 2008, hitting over RMB 860 billion in production value. NDRC has submitted policies for invigorating the industry to the State Council for approval. Three key national science and technology projects will commence this year - AIDS, prevention and treatment of viral hepatitis, as well as transgenic research. In addition, NDRC will work closely with the nine key bioindustry projects under China's Eleventh Five-Year Plan (2006-2011) to focus on the commercialization of green agricultural products, microorganism production, as well as modern TCM. (Click here for more - Chinese Language)
You may also be interested in...
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.